Cantor Fitzgerald Begins Coverage on Alpha Tau Medical (NASDAQ:DRTS)

Investment analysts at Cantor Fitzgerald assumed coverage on shares of Alpha Tau Medical (NASDAQ:DRTSGet Rating) in a research note issued to investors on Thursday, The Fly reports. The brokerage set an “overweight” rating and a $20.00 price target on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 89.04% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Alpha Tau Medical from a “hold” rating to a “sell” rating in a report on Wednesday, April 6th. Piper Sandler assumed coverage on shares of Alpha Tau Medical in a report on Friday, April 8th. They issued an “overweight” rating and a $19.00 price objective for the company. Finally, Citigroup assumed coverage on shares of Alpha Tau Medical in a report on Monday, April 4th. They issued a “buy” rating and a $21.00 price objective for the company.

Alpha Tau Medical stock opened at $10.58 on Thursday. Alpha Tau Medical has a one year low of $8.27 and a one year high of $20.65.

Alpha Tau Medical Company Profile (Get Rating)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers.

Featured Stories

The Fly logo

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.